Co-Written by Robin Kao
Sep 20, 2017 3:28:18 PM
Sep 19, 2017 3:58:14 PM
Join Leonard Fuld, Dr. Ben Gilad, and Ken Sawka in Boston, MA for their core certification courses. Competitive intelligence is not collecting random information. It's developing a skilled view of competitive risks and opportunities. Choose courses based on your interest or take all courses to become a certified CIP®.
Hotel discounted rate cut-off September 28, 2017
October registration October 23-27
Sep 14, 2017 10:15:52 AM
The U.S. is the largest market for pharmaceuticals, accounting for 30 to 40 percent of the worldwide market. However, newer smaller markets are on the rise for new drug products.
Sep 8, 2017 9:37:53 AM
Aug 24, 2017 11:32:00 AM
On August 14, 2017, Kenneth C. Frazier, Chairman and CEO of Merck, resigned from President Trump’s American Manufacturing
Aug 9, 2017 3:06:21 PM
The recent launch of Tesla’s mass-market vehicle, the Model 3, has people wondering what the connected car landscape will look like in the future. Tesla projects exponential sales growth, vastly exceeding current production capabilities. While Tesla is at the forefront of the headlines, other automobile manufactures, entertainment platform companies, data management companies, software and hardware companies scramble to dictate standards and stay relevant to the market dynamics of the automobile. What does this mean for the future of the automobile? Companies will partner, merge and acquire to avoid obsolescence caused by this breakneck speed of technological automobile innovation.
Aug 1, 2017 9:16:59 AM
With less than three years until the re-evaluation of HealthyPeople2020 Immunization targets, Benjamin Blumi, Senior Vice President of the American Pharmacists Association (APhA) Foundation, and his colleagues reported a dramatic breakthrough: in a study run from the fall of 2016 through spring of 2016, the number of pharmacist-administered adult vaccinations increased by more than 40 percent. A significant contributor to this success was Project IMPACT (IMProve American Communities Together), which features real time, bidirectional immunization information systems (IIS). The full breadth of this success, however, lies not exclusively with technology but with the adept interaction between information systems and patient-care processes.
Jul 27, 2017 3:48:16 PM
Drug pricing became a topic of common and passionate interest in 2015 when Martin Shkreli, then CEO of Turing Pharmaceuticals, dramatically increased the price of a single Daraprim tablet - from $13.50 to $750.00, the price of an average lunch to that of a large household appliance. The interest intensified in 2016, when Mylan increased the cost of the EpiPen by 400 percent. Public outcry was intense and politicians were forced to act, holding hearings that are only now rivaled by probes into Russian election interference.
Jul 26, 2017 3:38:49 PM
How do you set a business strategy in a highly-regulated market in which you don’t have complete control over what you can charge a segment of your customers, in which funds promised to your business by government agencies may be taken away, and in which rules governing what products you can sell can change at any time? Such is the life of strategic planners in U.S. health insurance companies.
Jul 20, 2017 12:24:05 PM
In part one of this blog, we discussed the scrutiny Lockheed Martin is facing due to the seemingly high cost of its helicopters and stealth fighters. We also established that value is a better metric, than looking at cost alone. But, regardless of how the true value of a program should be assessed and reported, Lockheed Martin must contend with how its various programs are in fact perceived by customers and other stakeholders. Conventional wisdom states that “the customer is always right.” Further, explaining to a concerned client why their concerns are irrelevant and unfounded is not a viable business model. What can Lockheed’s headaches with the F-35 and CH-53K teach us about client management?